PrintA Battle Brews for Control of Genzyme (.MP3,8.71 Mb)
In 2009, Genzyme stumbled as a viral contamination halted production at a key manufacturing plant, caused drug shortages for the company, and eventually financial disappointment to its investors. The missteps have left the smell of blood in the water and now activist investor Carl Ichan is seeking to win four board seats and wrest control of the company from its CEO Henri Termeer. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about Ichan’s efforts, what it means for Termeer and Genzyme, and how other biotechs that have fallen in the investor’s grasp have fared.
.gif)
.gif)
.gif)
